The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

Blood

Volumn 119, Issue 11, 2012, Pages 2590-2594

  De Rooij, Martin F M ^a   Kuil, Annemieke ^a   Geest, Christian R ^a   Eldering, Eric ^a   Chang, Betty Y ^b   Buggy, Joseph J ^b   Pals, Steven T ^a   Spaargaren, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CAL 101; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCL13 CHEMOKINE; FIBRONECTIN; FOSTAMATINIB; PCI 32765; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CELL ADHESION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPH NODE; LYMPHOCYTOSIS; LYMPHOMA CELL; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84858636448     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-390989     Document Type: Article

References (24)

1. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. (Pubitemid 40322252)
2. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009; 6(7):405-418.
3. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
4. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
5. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Semin Cancer Biol. 2010;20(6):424-430.
6. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokineand integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010; 115(22):4497-4506.
7. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109(4): 1660-1668. (Pubitemid 46242110)
8. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
9. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313-4320.
10. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199-227.
11. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075-13080.
12. Burger JA, O'Brien S, Fowler N, et al. The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 57.
13. Byrd JC, Blum KA, Burger JA, et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): interim results of a phase Ib/II study [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings). 2011;29(15):6508: Abstract 6508.
14. Fowler N, Sharman JP, Smith SM, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/ refractory B-cell malignancies: results from a phase I study [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 964.
15. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
16. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110gamma, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 55.
17. Koopman G, Keehnen RM, Lindhout E, et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol. 1994;152(8):3760-3767. (Pubitemid 24111046)
18. Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med. 2003; 198(10):1539-1550. (Pubitemid 37467168)
19. de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26(1): 93-104. (Pubitemid 46109347)
20. de Gorter DJ, Reijmers RM, Beuling EA, et al. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood. 2008;111(7):3364-3372.
21. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287- 6296.
22. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112(3):782-792.
23. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603- 3612.
24. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009;113(22):5549-5557.